MASSACHUSETTS GENERAL HOSPITAL

John Sims presented at CTAD that starting donanemab at low doses and titrating up reduced ARIA-E by 40%, especially for APOE homozygotes. Gil Rabinovici's new donanemab AUR emphasize stricter MRI criteria for safety. Lilly plans to submit data to update the label.

MDS management has evolved with novel therapies and molecular diagnostics, enhancing prognostic capabilities. COMMANDS trial results favor luspatercept over epoetin alfa in low-risk MDS, with more durable responses. Imetelstat shows promise in ESA-treated patients, while ivosidenib is effective for MDS with IDH1 mutations. Lenalidomide remains active in low-risk MDS with del(5q), and treatment sequencing strategies are advancing.

Becker's 2024 list highlights hospitals & health systems excelling in oncology, recognized for advanced clinical trials & research. Notable institutions include AdventHealth, Allina Health, Arkansas Children's, Atlantic Health System, Banner MD Anderson Cancer Center, Baylor Scott & White Health, Boston Medical Center, Brown University Health, Children's Health, Children's Hospital Colorado, Children’s Hospital Los Angeles, Children’s Hospital of Orange County, Children's Hospital of Philadelphia, Children's Nebraska, ChristianaCare, City of Hope Comprehensive Cancer Center, Cleveland Clinic, Connecticut Children’s, Covenant Health, Dana-Farber Cancer Institute, Dartmouth Health, DeTar Hospital Cancer Center, Duke Health, El Paso Children's Hospital, Emory Healthcare, Endeavor Health, Fred Hutchinson Cancer Center/UW Medicine, Geisinger, Hackensack Meridian Health, Huntsman Cancer Institute at the University of Utah, Inova, Jefferson Health, Johns Hopkins, Jupiter Medical Center, Keck Medicine of USC, Laredo Medical Center, Lehigh Valley Health Network, MUSC Health, MaineHealth, Massachusetts General Hospital, Mayo Clinic, MedStar, MemorialCare, Memorial Sloan Kettering Cancer Center, Michigan Medicine, Mount Sinai Health System, Nebraska Medicine, New York-Presbyterian Hospital-Columbia and Cornell, Northwestern Medicine, Novant Health, OSF HealthCare, OU Health, Ochsner Health, Ohio State University Comprehensive Cancer Center, Oregon Health & Science University Hospital, Orlando Health, Penn Medicine, Providence Alaska Medical Center, Providence Cancer Institute of Oregon, Providence South Division Cancer Institute, Queen's Health System, RWJBarnabas Health and Rutgers Cancer Institute, Renown Health, Rochester Regional Health, Roper St. Francis Healthcare, Roswell Park Comprehensive Cancer Center, Sanford Health, Sarasota Memorial Health Care System, Scripps Health, St. Jude Children's Research Hospital, Stanford Medicine, Stanford Medicine Children's Health, Sutter Health, Swedish Cancer Institute, Sylvester Comprehensive Cancer Center at University of Miami, Tampa General Hospital, Texas Children's Hospital, UC Davis Health, UCLA Health, UCSF Health, UK HealthCare, UNM Health System, UVA Health, UW Health, UMass Memorial Health, University of Alabama Birmingham Hospital, University of Chicago Medical Center, University of Colorado Cancer Center-UCHealth University of Colorado Hospital, University Hospitals, University of Iowa Health Care, University of Kansas Health System, University of Texas MD Anderson Cancer Center, University of Vermont Health Network, Vanderbilt University Medical Center, Virtua Health, WVU Cancer Institute, WellSpan Health, Yale New Haven Health.

Researchers found that specific immune cells from cancer immunotherapy cause myocarditis, distinct from cancer-fighting immune responses, suggesting potential for targeted treatments to avoid heart damage.

Aparna Parikh discusses HER2-positive colorectal cancer treatments, highlighting the MOUNTAINEER trial's trastuzumab and tucatinib combination and fam-trastuzumab deruxtecan-nxki (T-DXd) for HER2-amplified cases, considering KRAS mutation status.

rTMS targeting the default mode network (DMN) showed promising results in slowing cognitive decline, daily functioning, and behavioral symptoms in mild-to-moderate Alzheimer disease (AD) patients, according to a 12-month phase 2 trial presented at CTAD 2024.

Researchers identified immune and stromal cell changes in the heart underlying myocarditis in cancer patients on immune checkpoint inhibitors, pinpointing blood factors indicating mortality risk. The study suggests distinct immune responses in the heart and tumor, potentially enabling targeted therapies for myocarditis while maintaining antitumor immunotherapy.

Myocarditis driven by distinct immune response from anti-tumor one, suggesting future management without halting cancer therapy.

Sonrai Analytics is bringing its cloud-based AI technology to the Henri & Belinda Termeer Center for Targeted Therapies at MGH, enabling integration and analysis of diverse data types for faster insights. Sonrai Discovery will ensure data security and compliance, enhancing research output and collaborative efforts.

Sonrai Analytics will provide its AI technology to the Henri & Belinda Termeer Center at MGH, enabling integration and analysis of multi-omic data for personalized oncological therapies.